Celgene and LYSARC Provide Update on Phase III ‘RELEVANCE' Study of REVLIMID® in Combination with Rituximab (R²) for the Treatment of Previously Untreated Patients with Follicular Lymphoma

Celgene and LYSARC Provide Update on Phase III ‘RELEVANCE' Study of REVLIMID® in Combination with Rituximab (R²) for the Treatment of Previously Untreated Patients with Follicular Lymphoma